April, 2016 SMM-142
GSK’s Morality Gene
GSK’s recent decisions about pricing, transparency and return on investment seem to indicate an interesting new adaption to market conditions, one that is likely to be followed by the industry. This article will interest anyone interested in the life science industry’s ‘licence to operate’ in our society.